Trispecific CAR T Cells Show Promise in Cancer Trial
A 2026 phase 1 trial reports high response rates for patients with relapsed or refractory B-cell malignancies.
Updated on Oct. 20, 2026 in Cancer
Researchers at The Ohio State University James Comprehensive Cancer Center tested trispecific CAR T cells in 16 patients with B-cell malignancies. Published in 2026, the study findings reveal positive outcomes for participants with B-cell non-Hodgkin lymphoma.
Why it matters
The study offers a new approach to managing difficult-to-treat blood cancers where standard therapies have failed. Achieving high complete response rates with this method could improve long-term survival for oncology patients.
The phase 1 trial reported a 60.6% 1-year overall survival rate for the 16 treated patients. Researchers also noted a median CAR T-cell manufacturing time of 7 days with cytokine release syndrome occurring in 25% of the study participants.
The players
The Ohio State University James Comprehensive Cancer Center
This facility is a major cancer research and treatment institution located in Columbus that hosts clinical trials.
The details
Patients underwent lymphodepleting chemotherapy with cyclophosphamide and fludarabine before receiving the CAR T-cell infusion. The study used an open-label single-institution 3 + 3 dose-finding design to evaluate three different dose levels.
Timeline
Results from the phase 1 trial were published in 2026.
Four of five complete responders remained in remission 1 year after infusion.
Health Landscape
This study marks a transition from standard single-target therapies toward trispecific CAR T-cell designs. By moving beyond the single-antigen models that define current FDA-approved cellular immunotherapies, researchers are aiming to overcome resistance mechanisms in blood cancers.
Patients dealing with relapsed B-cell malignancies may find new hope in these trial results as the medical community explores multi-target cellular therapies. The 7-day manufacturing turnaround could eventually lead to faster access to customized treatments for those who currently have limited options.
The takeaway
The study suggests that trispecific therapies could provide a potent alternative for patients who fail to respond to traditional treatments. Ongoing research will focus on expanding this patient pool to ensure long-term efficacy and safety for a broader demographic.
Further reading
For more information on current treatment breakthroughs, visit the Cancer section.
Source note: This article includes information reported by Cancernetwork.
